Quick Answer
Alaunos Therapeutics, Inc. reported Research And Development Expense of $1.36 million for the year ending 2025.
- Alaunos Therapeutics, Inc. showed an increase of +276.5% in Research And Development Expense from 2024 to 2025.
- This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2009 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2009 to 2025), Alaunos Therapeutics, Inc.'s Research And Development Expense has declined by 70.1%.
- Historical annual values: Fiscal year 2025: $1.36 million | Fiscal year 2024: $362.0 thousand | Fiscal year 2023: $16.28 million | Fiscal year 2022: $25.02 million | Fiscal year 2021: $49.64 million | Fiscal year 2020: $52.70 million | Fiscal year 2019: $38.33 million | Fiscal year 2018: $34.13 million | Fiscal year 2017: $45.08 million | Fiscal year 2016: $157.79 million | Fiscal year 2015: $106.79 million | Fiscal year 2014: $32.71 million | Fiscal year 2013: $42.85 million | Fiscal year 2012: $83.45 million | Fiscal year 2011: $57.08 million | Fiscal year 2010: $17.50 million | Fiscal year 2010: $12.91 million | Fiscal year 2009: $4.56 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: